Phase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCD | oneSCDvoice
  • Join Today!

Become a member and connect with:

  • An Active Online Community
  • Articles and Advice on SCD
  • Help Understanding Clinical Trials

Phase 3 Trial Recruiting to Test Rivipansel for Vaso-Occlusive Crisis in SCD


GlycoMimetics, in collaboration with Pfizer, is now enrolling participants for a Phase 3 clinical trial to test the effectiveness and safety of the drug candidate rivipansel (GMI-1070) for the treatment of vaso-occlusive crisis (VOC) in hospitalized patients with sickle cell disease (SCD).
“We can report that the Phase 3 program to evaluate rivipansel for vaso-occlusive sickle cell crisis, according to our partner Pfizer, remains on track for completion in the second half of 2018,” Rachel King, CEO of GlycoMimetics, said in a press release.

https://www.onescdvoice.com/wp-content/uploads/2017/08/shutterstock_524592244.jpg